TNBC is the breast cancer subtype with the highest rates of tumor-infiltrating lymphocytes (TILs), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden, making it a prime candidate for immunoterapia [30,31]. The gene discussed is CD274; the disease is breast carcinoma.